HIGHLIGHT
Rybelsus

Rybelsus

semaglutide

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma

Marketer:

Novo Nordisk
Concise Prescribing Info
Contents
Semaglutide
Indications/Uses
Adjunct to diet & exercise in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate due to intolerance or contraindications; in combination w/ other medicinal products.
Dosage/Direction for Use
Initially 3 mg once daily for 1 mth. Maintenance dose: Increased to 7 mg once daily for at least 1 mth, may be increased to 14 mg once daily. Max single daily dose: 14 mg.
Administration
Should be taken on an empty stomach: Take on an empty stomach at any time of the day then wait at least 30 min before eating/drinking/taking other oral medicinal products. Swallow whole w/ a sip of water (up to half a glass of water equiv to 120 ml), do not cut/crush/chew.
Contraindications
Special Precautions
Discontinue in serious hypersensitivity reactions; pancreatitis. History of angioedema or anaphylaxis w/ another GLP-1 receptor agonist. Not to be used in patients w/ type 1 DM or for diabetic ketoacidosis; history of pancreatitis; previous hypersensitivity. Potential risk of dehydration. Increased risk of hypoglycaemia in combination w/ insulin or sulfonylurea. Not recommended in patients w/ CHF New York Heart Association (NYHA) class IV. Bariatric surgery. May affect ability to drive & use machines. Severe renal & hepatic impairment. Not recommended in end-stage renal disease. Women of childbearing potential must use contraception. Not to be used during pregnancy & lactation. Discontinue at least 2 mth before planned pregnancy. Childn & adolescents <18 yr. Elderly ≥75 yr.
Adverse Reactions
Hypoglycaemia; nausea, diarrhoea. Decreased appetite; vomiting, abdominal pain & distension, constipation, dyspepsia, gastritis, GERD, flatulence; fatigue; increased lipase & amylase.
Drug Interactions
Hypoglycaemia w/ insulin or sulfonylurea. Frequent INR monitoring w/ warfarin or other coumarin derivatives.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Rybelsus tab 14 mg
Packing/Price
10's;30's;60's;90's
Form
Rybelsus tab 3 mg
Packing/Price
10's;30's;60's;90's
Form
Rybelsus tab 7 mg
Packing/Price
10's;30's;60's;90's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in